MFGM-HMO Nutritional Composition for Higher DHA Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nutritional compositions often rely on expensive exotic ingredients for marginal improvements in bioavailability and health benefits, lacking synergistic combinations that could enhance nutrient uptake and promote health in humans of all ages while reducing health risks.
Innovation Solution
A nutritional composition comprising a milk fat globule membrane component, human milk oligosaccharides, and additional components like DHA, ARA, Vitamin E, and sphingomyelin, which synergistically enhance the bioavailability of nutrients such as DHA and alpha tocopherol, increasing their levels at the blood-brain barrier and in plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If expensive exotic ingredients are used in nutritional compositions, then bioavailability and health benefits are improved, but cost increases
Solution Approach 1:
The patent combines milk fat globule membrane (MFGM) with human milk oligosaccharides (HMOs) and other nutrients like DHA, ARA, and sphingomyelin to create a synergistic formulation. This merging of components enhances bioavailability and health benefits more effectively than using expensive exotic ingredients alone, while maintaining cost-effectiveness through the use of milk-derived components.
Solution Approach 2:
The nutritional composition uses a composite approach by integrating MFGM (containing phospholipids, glycolipids, and proteins) with HMOs and other essential nutrients. This composite formulation creates a synergistic effect that improves nutrient uptake and health outcomes without relying on costly exotic ingredients, achieving both reliability improvement and cost control.
2Quantity of substance
If standard ingredients are used in nutritional compositions, then cost is reduced, but bioavailability and health benefits are marginal
Solution Approach 1:
By merging MFGM with HMOs and essential nutrients (DHA, ARA, sphingomyelin, vitamins), the formulation achieves synergistic health benefits that exceed marginal improvements from standard ingredients alone. This combination enhances nutrient bioavailability and promotes infant health development while maintaining cost-effectiveness.
Solution Approach 2:
MFGM acts as an intermediary carrier that enhances the absorption and bioavailability of nutrients like DHA, ARA, and sphingomyelin. The phospholipids and glycolipids in MFGM facilitate nutrient uptake across the intestinal barrier, significantly improving health benefits compared to using standard ingredients without this intermediary carrier system.
3Productivity
If synergistic combinations of ingredients are used, then nutrient uptake is enhanced, but formulation complexity increases
Solution Approach 1:
The patent merges MFGM with HMOs and essential nutrients in a unified formulation that enhances nutrient uptake through synergistic interactions. The combination of phospholipids, glycolipids, proteins in MFGM with HMOs and nutrients like DHA, ARA, and sphingomyelin creates a coordinated system that improves absorption efficiency while managing formulation complexity through integrated design.
Solution Approach 2:
MFGM serves multiple functions simultaneously: it acts as a carrier for nutrients, provides phospholipids for cell membrane formation, contains glycolipids for neural development, and works synergistically with HMOs to enhance absorption. This multi-functionality allows the formulation to achieve enhanced nutrient uptake without proportionally increasing complexity, as one component performs multiple critical roles.
Data Source
AI summary
A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.